Published in Methods Enzymol on January 01, 2011
miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene (2012) 1.34
Targeting the unfolded protein response in glioblastoma cells with the fusion protein EGF-SubA. PLoS One (2012) 0.84
Molecular mechanisms of exopolysaccharide from Aphanothece halaphytica (EPSAH) induced apoptosis in HeLa cells. PLoS One (2014) 0.80
Targeting translation initiation in breast cancer. Translation (Austin) (2014) 0.75
Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions. J Bioenerg Biomembr (2016) 0.75
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res (2004) 2.35
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol (2012) 2.08
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med (2007) 1.99
The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys (2005) 1.83
Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler Thromb Vasc Biol (2009) 1.30
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther (2005) 1.16
Multiplexing with multispectral imaging: from mice to microscopy. ILAR J (2008) 1.08
Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther (2011) 1.08
Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomaterials (2006) 1.04
Imaging key biomarkers of tumor angiogenesis. Theranostics (2012) 1.03
Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia (2010) 1.02
In vivo tumor angiogenesis imaging with site-specific labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging (2006) 1.02
Radiation-induced gene translation profiles reveal tumor type and cancer-specific components. Cancer Res (2008) 1.00
Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth. Cancer Res (2013) 0.99
VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation. Am J Physiol Renal Physiol (2008) 0.98
Self-assembled "dock and lock" system for linking payloads to targeting proteins. Bioconjug Chem (2006) 0.97
Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anticancer Agents Med Chem (2006) 0.97
ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature. Nucl Med Biol (2010) 0.95
Inhibition of anthrax protective antigen outside and inside the cell. Antimicrob Agents Chemother (2006) 0.94
Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift? Neuro Oncol (2011) 0.94
Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med (2004) 0.93
In vivo, dual-modality OCT/LIF imaging using a novel VEGF receptor-targeted NIR fluorescent probe in the AOM-treated mouse model. Mol Imaging Biol (2011) 0.92
p75 neurotrophin receptor cleavage by α- and γ-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells. J Biol Chem (2014) 0.91
Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. Methods Mol Biol (2008) 0.90
Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys (2010) 0.90
Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J Nucl Med (2010) 0.90
Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT). Bioconjug Chem (2006) 0.90
Class I histone deacetylases localize to the endoplasmic reticulum and modulate the unfolded protein response. FASEB J (2012) 0.88
The impact of mid-treatment MRI on defining boost volumes in the radiation treatment of glioblastoma multiforme. Technol Cancer Res Treat (2004) 0.88
Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer. Neoplasia (2010) 0.88
Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol (2010) 0.87
Whole brain radiotherapy for brain metastasis. Surg Neurol Int (2013) 0.87
Molecular vehicles for targeted drug delivery. Bioconjug Chem (2002) 0.86
Imaging vascular endothelial growth factor (VEGF) receptors in turpentine-induced sterile thigh abscesses with radiolabeled single-chain VEGF. J Nucl Med (2009) 0.86
Fluorescence imaging of vascular endothelial growth factor in tumors for mice embedded in a turbid medium. J Biomed Opt (2010) 0.86
Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature. Adv Genet (2009) 0.86
SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF. Bioconjug Chem (2009) 0.85
Targeting the unfolded protein response in glioblastoma cells with the fusion protein EGF-SubA. PLoS One (2012) 0.84
PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model. Eur J Nucl Med Mol Imaging (2011) 0.83
The emerging role of histone deacetylases (HDACs) in UPR regulation. Methods Enzymol (2011) 0.83
LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol (2014) 0.83
Molecular imaging of vascular endothelial growth factor receptors in graft arteriosclerosis. Arterioscler Thromb Vasc Biol (2012) 0.83
Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m. Bioconjug Chem (2008) 0.83
Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother (2014) 0.83
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. J Neurooncol (2010) 0.82
Adapter protein for site-specific conjugation of payloads for targeted drug delivery. Bioconjug Chem (2004) 0.82
Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery. Protein Expr Purif (2002) 0.81
Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis. J Nucl Med (2011) 0.81
Fractionated stereotactic radiotherapy to the post-operative cavity for radioresistant and radiosensitive brain metastases. J Neurooncol (2014) 0.80
Simulation of intrafraction motion and overall geometrical accuracy of a frameless intracranial radiosurgery process. J Appl Clin Med Phys (2008) 0.78
Outcomes Following Hypofractionated Stereotactic Radiotherapy in the Management of Brain Metastases. Am J Clin Oncol (2016) 0.77
Assembly of targeting complexes driven by a single-chain antibody. J Immunol Methods (2004) 0.77
Humanized docking system for assembly of targeting drug delivery complexes. J Control Release (2003) 0.77
Chimeric ribonuclease as a source of human adapter protein for targeted drug delivery. Protein Eng (2003) 0.76
SLT-VEGF reduces lung metastases, decreases tumor recurrence, and improves survival in an orthotopic melanoma model. Toxins (Basel) (2010) 0.75
Imaging VEGF receptor expression to identify accelerated atherosclerosis. EJNMMI Res (2014) 0.75
A "dock and lock" approach to preparation of targeted liposomes. Methods Mol Biol (2010) 0.75
Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. J Neurooncol (2014) 0.75